Anecortave Acetate Risk-Reduction Trial (AART)

This study has been completed.

First Received: March 24, 2006 Last Updated: May 7, 2009 History of Changes

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00307398

Purpose

A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.

Condition	Intervention	Phase
Dry AMD	Drug: Anecortave Acetate	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	Anecortave Acetate Risk-Reduction Trial (AART)

Resource links provided by NLM:

Drug Information available for: Anecortave acetate

Further study details as provided by Alcon Research:

Primary Outcome Measures:

To demonstrate that anecortave acetate is safe and effective in arresting the progression of dry AMD to wet AMD in at-risk patients

Secondary Outcome Measures:

Estimated Enrollment:	2500
Study Start Date:	March 2004
Estimated Study Completion Date:	February 2010
Primary Completion Date:	January 2009 (Final data collection date for primary outcome measure)

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00307398

Locations

United States, Texas
Study Centers in the United States and Globally
Fort Worth, Texas, United States, 76134

Sponsors and Collaborators

Alcon Research

Investigators

Study Director:

Patricia Zilliox

Study Manager

More Information

No publications provided

Study ID Numbers:	C-02-60
Study First Received:	March 24, 2006
Last Updated:	May 7, 2009
ClinicalTrials.gov Identifier:	NCT00307398 History of Changes
Health Authority:	United States: Food and Drug Administration

Keywords provided by Alcon Research:

AMD
Dry AMD
Drusen
CNV

ClinicalTrials.gov processed this record on September 11, 2009